Regen BioPharmaRGBP +7.14% FCF Yield % is -619.48 as of Jul. 11, 2026. The stock has 7 warning signs investors should review. Among 1,408 Biotechnology companies, Regen BioPharma ranks worse than 98.65% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Regen BioPharma FCF Yield % Related Terms
Regen BioPharma FCF Yield % Historical Data
* Premium members only.
The historical data trend for Regen BioPharma's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Regen BioPharma's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regen BioPharma FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regen BioPharma's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Regen BioPharma's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regen BioPharma (RGBP) has a FCF Yield % of -619.48 as of Jul. 11, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Regen BioPharma and its competitors. According to the industry distribution chart, Regen BioPharma ranks #1389 out of 1408 companies in the Biotechnology industry, placing it in the top 98.7%.
Is Regen BioPharma's FCF Yield % too high?
Regen BioPharma's current FCF Yield % is -619.48. Based on the distribution chart, Regen BioPharma ranks #1389 out of 1408 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Regen BioPharma's FCF Yield % compare to SIGY and ENDV?
According to the Biotechnology industry distribution chart, Regen BioPharma ranks #1389 out of 1408 companies for FCF Yield %. This places Regen BioPharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Regen BioPharma and its competitors. Regen BioPharma's current FCF Yield % is -619.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regen BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Regen BioPharma (RGBP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.02, compared to a current price of $0.00 — trading 99.3% below its estimated fair value. The current FCF Yield % is -619.48. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Regen BioPharma (RGBP), the current FCF Yield % is -619.48 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regen BioPharma Inc is a USA-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II are cellular therapies designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGBP has been successfully added to your 